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ABSTRACT
Objective: The objective of the study was to assess the pleiotropic effects of Sitagliptin as add-on therapy to the conventional antidiabetic drugs.
Methods: This was designed as a prospective study. 140 patients with type 2 diabetes mellitus (T2DM) whose glycated hemoglobin (HbA1c) 
was >7% despite receiving education on diet and exercise and/or medications were enrolled in this study. Sitagliptin (100 mg) was administered 
once a day orally for 6 months as an add-on therapy with the conventional antidiabetic drugs. The outcome of the therapy was assessed on the 
level of improvement in the fasting plasma glucose, postprandial plasma glucose, HbA1c levels, lipid profile, body mass index, blood pressure, and 
albuminuria in the third and 6th month when compared to the first visit.
Results: After 6 months of treatment with Sitagliptin, fasting blood glucose levels significantly reduced (202.6±49.21 to 186.1±50.14, p=0.029) as 
well as HbA1c (9.5±1.27 to 9.1±1.28, p=0.016). There was a statistically significant (p<0.001) reduction of blood pressure, cholesterol, and urinary 
albumin-creatinine ratio progressively.
Conclusion: Sitagliptin has a significant effect on lipid profile, blood pressure and albuminuria in addition to its effect on blood glucose profile and 
HbA1c without many side effects, in patients with T2DM.
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INTRODUCTION
Diabetes mellitus is a group of metabolic diseases characterized by 
hyperglycemia resulting from defects in insulin secretion, insulin 
action, or both [1]. The International Diabetes Federation assesses the 
total number of diabetic subjects to be 425 million people, in 2017, in 
comparison with 50.8 million in 2010 [2]. In urban areas of Tamil Nadu, 
diabetes prevalence was higher in people with lower socioeconomic 
status [3]. Over the past 30 years, the status of diabetes has transformed 
from a mild disorder of the aged to one of the most important causes of 
mortality and morbidity for the youth and middle-aged people [4]. The 
greater part of diabetes mellitus falls into two wide etiopathogenetic 
classes. In one class, type 1 diabetes, there is an absolute deficiency of 
insulin secretion. Individuals at risk of developing type 1 diabetes can 
frequently be identified by the serological testimony of an autoimmune 
process taking place in the pancreatic islets and also by genetic 
markers. In the other, much more common class, type 2 diabetes, 
the cause is a combination of insulin resistance and an inadequate 
compensatory insulin secretory response. The basis of the derangement 
in carbohydrate, protein, and fat metabolism in diabetes is the 
insufficient action of insulin on target tissues. Deficient insulin action 
results from insufficient secretion of insulin and/or weakened tissue 
responses to insulin at points in the pathways of insulin action. Loss 
of first-phase insulin secretion and diminished second-phase secretion 
are the typical features of type 2 diabetes mellitus (T2DM); and it is 
recognized that a reduction in the first-phase of insulin secretion is 
seen in impaired glucose tolerance and the initial stage of T2DM [5,6]. 
Symptoms of marked hyperglycemia consist of polydipsia, polyuria, 
loss of weight, and occasionally with polyphagia and blurred vision. 
Life-threatening acute complications of uncontrolled diabetes are non-
ketotic hyperosmolar syndrome or hyperglycemia with ketoacidosis. 
Diabetes can be diagnosed by the presence of symptoms of diabetes 
with random plasma glucose concentration ≥200 mg/dl or fasting 
plasma glucose ≥126 mg/dl on 2 occasions or 2 h plasma glucose 
during oral glucose tolerance test ≥200 mg/dl or glycated hemoglobin 
(HbA1c) ≥6.5% [7].
Long-term complications of diabetes include nephropathy leading to 
renal failure; peripheral neuropathy with the hazard of foot ulcers, 
amputations, and Charcot joints; retinopathy with potential loss 
of vision and autonomic neuropathy leading to gastrointestinal, 
cardiovascular and genitourinary symptoms, and sexual dysfunction. 
Diabetic patients have a greater incidence of atherosclerotic peripheral 
arterial, cardiovascular, and cerebrovascular disease. Abnormalities 
of lipoprotein metabolism and hypertension are frequently seen in 
patients with diabetes.
The salient feature of diabetic nephropathy is albuminuria, which 
can be screened by the measurement of urine albumin to creatinine 
ratio in a random spot sample. It includes both microalbuminuria 
(30–299 mcg/mg creatinine) and macroalbuminuria (≥300 mcg/mg 
creatinine) [8]. The incidence of microalbuminuria is about 25.5% in 
T2DM patients [9].
The treatment of T2DM includes the use of various drugs in the first 
line of management which may result in a progressive decline in 
β cell function. Currently available oral antidiabetic drugs include 
insulin secretagogues, insulin sensitizers, and drugs acting by other 
mechanisms. They are sulfonylureas, meglitinides, biguanides, 
thiazolidinediones, and alpha-glucosidase inhibitors. They possess 
adverse effects such as weight gain and hypoglycemia (with 
sulfonylureas), edema (with thiazolidinediones), and lactic acidosis 
(with biguanides) and they are restricted for use in renal and hepatic 
dysfunction. UKPDS has demonstrated that there is a progressive ß-cell 
failure despite treatment with the above drugs [10]. Hence, the perfect 
antidiabetic drug must delay or reverse the cell decline, which can be 
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used concomitantly with current drugs, with no additional or serious 
adverse drug reaction profile, thus minimizing long-term complications 
and mortality.
The study of incretin hormones and entero-insular axis resulted in 
the discovery of two groups of antidiabetic agents - the glucagon-like 
peptide 1 (GLP-1) analogs and the dipeptidyl peptidase IV (DPP-IV) 
inhibitors [11]. Oral delivery of glucose produces a greater release 
of insulin as compared to intravenous glucose. Glucose-dependent 
insulinotropic polypeptide and GLP-1 are released from the intestines 
and enhance glucose-dependent insulin secretion. These hormones 
are named incretins. GLP-1 considerably augments glucose-dependent 
insulin secretion and subsequently has become a striking target for 
therapeutic development in type 2 DM [12]. GLP-1 also reduces glucagon 
secretion, slows gastric emptying, and decreases appetite. Thus, it 
reduces postprandial glucose excursions and also induces weight loss. 
Counteracting these advantages, circulating GLP-1 is rapidly inactivated 
by the DPP-IV within 1–2 min [13]. Hence, the goal of therapy is to 
inactivate the DPP-IV enzyme, thus increasing endogenous GLP-1 
levels. Various orally effective DPP-IV inhibitors include Sitagliptin, 
Vildagliptin, Saxagliptin, Linagliptin, and Teneligliptin, now available 
for therapy of type 2 diabetes in India.
Sitagliptin is the prototype and the first approved member of 
DPP- IV inhibitor class. It is a potent, highly selective, reversible, and 
competitive inhibitor of DPP-IV enzyme. It was approved by the US 
Food and Drug Administration in 2006. It has a half-life of 12.4 h and 
is given as 100 mg tablet once daily. It can be used as monotherapy 
or add on to metformin/sulfonylureas/pioglitazone/insulin. Adverse 
effects are nasopharyngitis, headache, and hypoglycemia when used 
with sulfonylureas. Hence, while combining with a sulfonylurea, the 
dose of sulfonylurea should be reduced to 50% to minimize the risk of 
hypoglycemia. It has high patient compliance rate due to its advantage 
of once-daily dosing. Dose adjustment of Sitagliptin is required 
in moderate and severe renal impairment. Sitagliptin has many 
advantages over other DPP-IV inhibitors. Sitagliptin is well tolerated 
and can be given once daily in contrast to Vildagliptin, which may cause 
hepatotoxicity and is given twice daily. There are also no interactions 
with other drugs which are an advantage over Saxagliptin. It has 
been shown that chronic Sitagliptin treatment resolved the metabolic 
derangement, hypertriglyceridemia, inflammation, reduced the 
severity of the pancreatic endocrine, and exocrine lesions and corrected 
hypertension [14]. Hence, we chose Sitagliptin for our present study.
Objective
The objective of this study was to determine the pleiotropic effects of 
Sitagliptin as add-on therapy to the conventional antidiabetic drugs. 
Primary endpoints were a reduction in HbA1c and reduction of fasting 
and postprandial blood glucose. Secondary endpoints were a reduction 
of cholesterol levels, reduction of systolic and diastolic blood pressure, 
reduction of albuminuria, and reduction of body mass index (BMI).
MATERIALS AND METHODS
Institutional Ethics Committee approved this study (Ethics clearance 
No. 566/IEC/2014), and informed consent was obtained from all 
participants. Patients with T2DM (age ≥18 years) whose HbA1c 
was >7% despite receiving education on diet and exercise and/ or 
medications were enrolled in this study. The sample size was estimated 
as 140 using the formula, with the precision error of 5%, type 1 
error of 5%, and 10% attrition [15]. The exclusion criteria were a 
history of hypersensitivity to any DPP-4 inhibitor, renal dysfunction 
(serum creatinine: male ≥1.5 mg/dl and female ≥1.3 mg/dl), serum 
triglyceride (TGL) levels >300 mg/dL, pregnancy, lactation, and females 
of childbearing potential. For the study subjects, Sitagliptin was given 
either as a new prescription or as an add-on to conventional antidiabetic 
drugs. Before entering the study, 9 patients had been treated only with 
diet and exercise. 54 patients had been receiving glimepiride, which was 
reduced to 2 mg/day or less on entry. Moreover, the dose of glimepiride 
was reduced to half or stopped when HbA1c was reduced by >0.5% 
by the next visit. Metformin (n=72) and Pioglitazone (n=33) that 
patients had been taking before this study commenced, were continued 
throughout the study without any change in the dosing. 48 patients 
were taking Angiotensin II receptor blockers, and 10 patients were 
taking HMG-CoA reductase inhibitors (statins); both of these were 
continued throughout the study without dose modification. Sitagliptin 
100 mg was administered orally once daily for 6 months.
Clinical measurements
Physical examination (including measurement of blood pressure and 
BMI) and laboratory tests such as fasting and postprandial blood 
glucose, HbA1c, total cholesterol (TC), TGLs, high-density lipoprotein, 
low-density lipoprotein, very low-density lipoprotein, and urinary 
albumin creatinine ratio (ACR) were performed at the starting point, 
3 months, and 6 months after starting treatment with Sitagliptin.
Plasma glucose estimation was done using glucose oxidase-peroxidase 
(POD) method. HbA1c estimation was done using high-performance 
liquid chromatography method. TC was estimated using cholesterol 
oxidase and POD enzymatic colorimetric method. TGL estimation was 
done by the enzymatic glycerol phosphate oxidase and POD method. 
High-density lipoprotein (HDL), cholesterol estimation was performed 
by direct immunoinhibition method. Low-density lipoprotein (LDL) and 
very low-density lipoprotein (VLDL) were calculated using the formulae:
LDL=TC-HDL-(TGL/5) and VLDL=TGL/5.
Spot urinary ACR was estimated using immunoturbidimetry.
Baseline characteristics
A total of 140 patients were enrolled into this study, of 
whom130 (51 males and 79 females) with a mean age of 53.8 years 
were successfully followed over 6 months of Sitagliptin treatment. 
Fig. 1: Study enrolment
Fig 2: Sex distribution
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Table 2: Effect of Sitagliptin on various parameters measured at baseline, 3rd month, and 6th month of treatment
S. No. Parameter Mean±SD p value
Visit 1 Visit 2 Visit 3 Overall Visit 1 versus 
Visit 2
Visit 1 versus 
Visit 3
Visit 2 versus 
Visit 3
1 Fasting blood glucose 202.6±49.21 193.3±49.78 186.1±50.14 0.029 <0.001 <0.001 <0.001
2 Postprandial blood glucose 283.3±62.29 272.6+61.95 265.7±2.31 0.074 <0.001 <0.001 <0.001
3 Glycated hemoglobin 9.5±1.27 9.2±1.25 9.1±1.28 0.016 <0.001 <0.001 <0.001
4 Systolic blood pressure 126.8±5.89 125.4±5.6 123.4+5.44 <0.001 <0.001 <0.001 <0.001
5 Diastolic blood pressure 81.5±4.23 80.1+4.09 78.8±4.18 <0.001 <0.001 <0.001 <0.001
6 Body mass index 26.5±2.44 26.4±2.47 26.2±2.49 0.0738 <0.001 <0.001 <0.001
7 Urine albumin creatinine 
ratio
159.2±124.65 135±110.78 114±99.48 0.005 <0.001 <0.001 <0.001
8 Total cholesterol 178.7±34.05 173.1±32.89 168.6±32.56 0.05 <0.001 <0.001 <0.001
9 Triglycerides 145.1±49.91 135.5±47.42 127.8±45.88 0.14 <0.001 <0.001 <0.001
10 High-density lipoprotein 31.7±7.76 34.5+7.33 37.1±7.58 <0.001 <0.001 <0.001 <0.001
11 Low-density lipoprotein 118±31.78 111.8±30.93 105.9±31.11 0.008 <0.001 <0.001 <0.001
12 Very low-density 
lipoprotein
28.7±10.2 26.8±9.51 25.2±9.14 0.016 <0.001 <0.001 <0.001
SD: Standard deviation
Mean BMI was 26.5±2.44 kg/m2 and mean duration of diabetes was 
9.5±4.8 years among these130 patients at the beginning of the study.
Statistical methods
Statistical analysis was done using Statistical Package for the Social 
Sciences. All data measurements were at least on an interval scale. Hence, 
the descriptive statistics (mean, standard deviation, median, minimum, 
and maximum values) as applicable were described using frequency 
tables. Paired t-test was used to test differences between mean values 
between three different time points taking two-points at a time. One-
way ANOVA was employed to test for overall differences between all 
three time-points together. Box-plots were drawn to pictorially depict 
the scenarios of each variable at three different time points.
RESULTS AND DISCUSSION
Effect of Sitagliptin on glycemic control
In our study, the mean reduction in fasting blood glucose between the 
three visits was 9.3 (Visit 1 vs. Visit 2), 7.6 (Visit 2 vs. Visit 3), and 
16.5 (Visit 1 vs. Visit 3) which was statistically significant (p=0.029). 
Fig. 3: Box-plot showing serial changes at baseline, 3rd month, and 6th month (depicts median, 1st and 3rd quartile, minimum and 
maximum values with outliers identified). (a) Fasting plasma glucose (FPG). (b) Postprandial plasma glucose (PPBG). (c) Glycated 
hemoglobin (HbA1c)  
The mean reduction in postprandial blood glucose (PPBG) between 
the three visits was 10.7 (Visit 1 vs. Visit 2), 6.9 (Visit 2 vs. Visit 3), 
and 17.6 (Visit 1 vs. Visit 3) which was statistically insignificant 
(p=0.074). The mean reduction in HbA1c between the three visits 
was 0.3 (Visit 1 vs. Visit 2), 0.1 (Visit 2 vs. Visit 3), and 0.4 (Visit 1 vs. 
Visit 3) which was also statistically significant (p=0.016) (Fig. 3 and 
Table 2).
Our results were similar to those of previous studies reported 
in the United States of America and Japan [16,17]. Nathan et al. 
reported that the estimated decrease in HbA1clevels is 1–2% with 
metformin monotherapy, 1–2% with sulfonylureas, 0.5–1.4% 
with thiazolidinediones, 0.5–1% with meglitinides, 0.5–0.8% with 
α-glucosidase inhibitors, and 0.5%–0.8% with DPP-IV inhibitors [18].
However, metformin is associated with gastrointestinal side effects; 
sulfonylureas are associated with hypoglycemic episodes and 
thiazolidinediones with cardiac failure, which is not associated with the 
utilization of DPP-IV inhibitors [17,19].
Although mild side effects such as diarrhea were seen in 3 patients 
and 1 patient had nasopharyngitis, they were self-limiting and quite 
manageable. None of the patients experienced hypoglycemia with 
Sitagliptin.
Effects of Sitagliptin on lipid profile and blood pressure
In our study TGL, LDL, and TC progressively decreased between the 
visits; reduction in TGL was not statistically significant (p=0.14), 
whereas the reduction in TC and LDL was statistically significant 
(p=0.05 TC, p=0.008 LDL). Moreover, there was a statistically significant 
cba
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visits in our study (Fig. 5 and Table 2). GLP-1 demonstrates vascular effects 
through GLP-1 receptor signaling [22]. In addition, a metabolite of GLP-1 
has vasodilator properties independent of the GLP-1 receptor in nitric 
oxide/ cyclic guanosine monophosphate-dependent manner [22]. DPP-4 
inhibitors amplify the levels of GLP-1, probably leading to vasodilatation and 
reduction of blood pressure. GLP-1 also increases the excretion of sodium in 
the proximal renal tubule in insulin-resistant obese persons. Therefore, GLP-
1-induced amplification in urinary sodium excretion might also contribute 
to the reduction of blood pressure after Sitagliptin treatment [23].
Effect of Sitagliptin on albuminuria
In our study, there was a statistically significant (p=0.005) reduction of 
albuminuria (urinary ACR) progressively during the three visits (Fig. 5 
and Table 2). One of the mechanisms of albuminuria reduction might be 
the initiation of reasonable blood glucose control. Sitagliptin reduces 
glucose fluctuation by reducing fasting and PPBG which might inhibit 
vascular inflammation [24].
Increased active GLP-1 levels also could inhibit vascular inflammation 
which accounts for another mechanism. It has been reported that 
GLP-1 inhibits upregulation of VCAM-1 mRNA levels in the endothelial 
cells of blood vessels, induced by advanced glycation end products, at 
concentrations which Sitagliptin treatment has been shown to reach 
[25]. GLP-1 receptor was proven to be present on endothelial cells of 
the human umbilical vein, and its presence was confirmed in human 
glomerular endothelial cells also. Thus, Sitagliptin may exert an anti-
inflammatory effect in the kidney through GLP-1 receptor by augmenting 
active GLP-1, causing the decrease of albuminuria. The anti-inflammatory 
effect of GLP-1 by the involvement of the cyclic AMP/Protein Kinase A 
pathway may also contribute to reducing albuminuria [26].
Effect of Sitagliptin on BMI
Although it has been proved in many studies that DPP-IV inhibitors 
are neutral on weight, our study showed there was a mild, statistically 
insignificant (p=0.07) reduction in BMI progressively (Fig. 5 and 
Table 2) [27].
LIMITATIONS OF THE STUDY
Since this was a non-randomized study, the pleiotropic effects of 
Sitagliptin as add-on therapy were not clearly derived. To know the 
Fig. 4: Serial changes in lipid profile at baseline, 3rd month, and 
6th month (TC: Total cholesterol, TGL: Triglycerides, HDL: High-
density lipoprotein, LDL: Low-density lipoprotein, and VLDL: Very 
low-density lipoprotein)
Fig. 5: Effect of Sitagliptin on (a) systolic blood pressure, (b) diastolic blood pressure, (c) body mass index, and (d) urine albumin-
creatinine ratio (Visit 1 - baseline, Visit 2–3rd month, and Visit 3–6th month)
(p<0.001) rise in HDL cholesterol between the three visits in our study, 
which is cardioprotective (Fig. 4 and Table 2).
Qin et al. showed that GLP-1 reduces the intestinal lymphatic flow 
and also reduces TGL absorption and production of apo B and apo 
AIV in rats [20]. Prolonged DPP-4 inhibition alters the genes essential 
for fatty acid oxidation, including acyl-coenzyme dehydrogenase 
medium chain and Acyl-CoA synthetase. In addition, DPP-IV inhibitors 
decrease the levels of hepatic mRNA transcripts for acetyl coenzyme 
A acyltransferase 1 and carnitine palmitoyltransferase 1 [21]. Because 
these modulations are based on incretin receptor actions, Sitagliptin 
may have the ability to decrease the levels of TC and TGL.
There was a statistically significant (p<0.001) reduction of both systolic 
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unbiased effects of Sitagliptin, a randomized multicentric double-
blinded control study with Sitagliptin in one arm and placebo in another 
arm along with conventional antidiabetic drugs in both the groups can 
be done in the future. Furthermore, the drug is very expensive, which 
puts the affordability of all the patients into question.
CONCLUSION
The clinical use of the DPP-4 inhibitor Sitagliptin has beneficial effects 
not only on blood glucose control but also for improving blood pressure, 
lipid profile, and albuminuria in addition to a high rate of adherence to 
treatment.
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